Shares of Lexicon Pharmaceuticals LXRX were unchanged after the company reported Q2 results.
Quarterly Results
Earnings per share were up 80.00% over the past year to ($0.13), which beat the estimate of ($0.16).
Revenue of $234,000 decreased by 97.45% year over year, which beat the estimate of $10,000.
Looking Ahead
Earnings guidance hasn't been issued by the company for now.
Revenue guidance hasn't been issued by the company for now.
How To Listen To The Conference Call
Date: Jul 30, 2021
Time: 08:00 AM
ET Webcast URL: https://www.webcaster4.com/Webcast/Page/897/42157
Technicals
Company's 52-week high was at $9.65
Company's 52-week low was at $1.03
Price action over last quarter: down 21.83%
Company Description
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development and commercialization of pharmaceutical products for the treatment of human disease. Some of its drugs candidates are LX9211, an orally-delivered small molecule drug candidate, as a treatment for neuropathic pain; and sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for heart failure and type 1 diabetes.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Date | ticker | name | Actual EPS | EPS Surprise | Actual Rev | Rev Surprise |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.